RWE: CIBMTR
Efficacy
PFS by JULIET eligibility
OS at 12 months
60%
ORR
57%
CR
42%
| Safety | |
|---|---|
| CRSGrade ≥3 | 8% |
| ICANSGrade ≥3 | 8% |
67% of CIBMTR patients would have been ineligible for the JULIET trial. Similar outcomes were shown in JULIET eligible and ineligible patients
- Reference: 1. Landsburg DJ et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 429.
Efficacy
PFS by JULIET eligibility
ORR
%
CR
%
OS at 24 months
%
| Safety | |
|---|---|
| CRSGrade ≥3 | % |
| ICANSGrade ≥3 | % |
Patients with comorbidities (~44%) derived similar benefit to those without, with comparable safety1
- Reference: 1. Landsburg DJ et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Presentation 656.
Data collection1
May 2018–May 2022
US, Canada and Israel
Median follow-up
~ years1
No. of patients infused with tisa-cel1
(968 in efficacy set)
| Median age (range) yearsPatients ≥65 years | 66.5 (14–91)55% |
| Gender (male) | 59% |
| ECOG ≥2 | 5% |
| IPI | NR |
| HG lymphoma (double or triple hit) | 13%11% |
| DLBCL | 81% |
| Transformed lymphoma | 28% |
| Comorbidities | 55% |
| LDH elevated | NR |
| Prior therapies (median)≥2 lines | 3 (0–11)84% |
| Primary refractoryRefractory to last lineRelapsed | 38%NR54% |
| Prior SCTAutoAllo | 26%2% |
| Bridging therapy | NR |
| Median time from receipt of apheresis product at manufacturing site to shipment | 26 days |
Largest RWE source but with some limitations: No information on bridging therapy, ECOG data missing for 15%, some data issues
- Patient characteristics shown are from 17-month follow-up2 as data are missing from 2 year follow-up.
- References: 1. Landsburg DJ et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Presentation 656.
- 2. Landsburg DJ et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 429.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete